Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06416800
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Statins Role in Acute Ischemic Stroke
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 105
- Registration Number
- NCT06371495
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 72
- Registration Number
- NCT06348290
Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-03-29
- Target Recruit Count
- 40
- Registration Number
- NCT06338293
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT06329895
- Locations
- 🇬🇧
PAREXEL International Early Phase Clinical Unit (London), Harrow, United Kingdom
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Arab Contractors Medical Centre
- Target Recruit Count
- 150
- Registration Number
- NCT06304896
- Locations
- 🇪🇬
Arab Contractors Medical Centre, Cairo, Egypt
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eccogene
- Target Recruit Count
- 48
- Registration Number
- NCT06293742
- Locations
- 🇺🇸
Eccogene Investigational Site, Anaheim, California, United States
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 122
- Registration Number
- NCT06279234
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT06191991
- Locations
- 🇺🇸
PPD Austin Research Unit, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.